Aerie Pharmaceuticals, Inc. (AERI) News
Filter AERI News Items
AERI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AERI News Highlights
- For AERI, its 30 day story count is now at 21.
- Over the past 14 days, the trend for AERI's stories per day has been choppy and unclear. It has oscillated between 1 and 8.
- EYE, AR and DOW are the most mentioned tickers in articles about AERI.
Latest AERI News From Around the Web
Below are the latest news stories about Aerie Pharmaceuticals Inc that investors may wish to consider to help them evaluate AERI as an investment opportunity.
Pharma Stock Roundup: ABBV's Deal With RGNX, LLY COVID Drug's Government Order WinAbbVie (ABBV) buys rights to Regenexbio's gene therapy candidate for chronic retinal diseases. Lilly (LLY) will supply additional doses of its COVID-19 antibody medicine to the U.S. government. |
56 Biggest Movers From YesterdayCheck out these big penny stock gainers and losers Losers Vera Therapeutics, Inc. (NASDAQ: VERA) shares tumbled 26.5% to settle at $22.48. MacroGenics, Inc. (NASDAQ: MGNX) fell 23.8% to close at $20.99 as the company disclosed results from Cohort A Part 1 of the Phase 2/3 MAHOGANY clinical trial of margetuximab. Silverback Therapeutics, Inc. (NASDAQ: SBTX) shares dipped 23.1% to close at $12.50 on Thursday. The company presented interim clinical results from a Phase 1/1b clinical study of SBT605 |
Aerie Pharma Reports Mixed Bag On Phase 2 Dry Eye TrialAerie Pharmaceuticals Inc (NASDAQ: AERI ) announced topline results of its Phase 2b COMET-1 study evaluating AR-15512 (TRPM8 Agonist) ophthalmic solution for dry eye disease. The company said that the study failed to achieve statistical significance at pre-determined primary endpoints at Day 28. However, the ophthalmic solution reached statistical significance over multiple pre-specified symptoms and signs, Aerie added. Aerie observed the most significant efficacy Full story available on Benzinga.com |
Why The Future Is Cloudy For This Aerie Pharmaceuticals Drug As Shares PlummetAerie Pharmaceuticals missed the mark in a dry-eye disease test, leading AERI stock to plummet to a 10-month low Thursday. |
Mid-Afternoon Market Update: Dow Falls 70 Points; Aerie Pharmaceuticals Shares PlungeToward the end of trading Thursday, the Dow traded down 0.20% to 34,745 while the NASDAQ fell 0.03% to 15,157.61. The S&P also fell, dropping 0.21% to 4,471.34. The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 41,539,100 cases with around 666,620 deaths. India confirmed a total of at least 33,347,320 cases and 443,920 deaths, while Brazil reported over 21,034,610 COVID-19 cases with 588,590 deaths. In total, there were at least 226,445,290 cases |
Aerie (AERI) Announces Mixed Data From Dry Eye Disease StudyAerie Pharmaceuticals (AERI) reports mixed data from the phase IIb study evaluating AR-15512 for treating dry eye disease. Resultantly, the stock declines in after-market trading on Sep 15. |
Mid-Morning Market Update: Markets Down; US Retail Sales Unexpectedly Increase in AugustFollowing the market opening Thursday, the Dow traded down 0.45% to 34,657.69 while the NASDAQ fell 0.66% to 15,061.97. The S&P also fell, dropping 0.62% to 4,453.04. The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 41,539,100 cases with around 666,620 deaths. India confirmed a total of at least 33,347,320 cases and 443,920 deaths, while Brazil reported over 21,034,610 COVID-19 cases with 588,590 deaths. In total, there were at least 226,445,290 |
Aerie Pharmaceuticals Announces Novel Dry Eye Product Candidate AR-15512 (TRPM8 Agonist) Ophthalmic Solution Achieved Statistical Significance Over Multiple Symptoms and Signs in Successful Phase 2b Clinical Study for the Treatment of Dry Eye DiseaseDURHAM, N.C., September 15, 2021--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today reported positive topline results of its Phase 2b clinical study, named COMET-1, for AR-15512 (TRPM8 Agonist) ("AR-15512") ophthalmic solution for the treatment of patients with dry eye dise |
Aerie Pharmaceuticals Announces Appointment of Carolyn McAuliffe, Senior Director, CommunicationsDURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced the appointment of Carolyn McAuliffe, Senior Director, Communications, reporting to Tad Heitmann, Aeries Vice President of Marketing. Ms. McAuliffe will be responsible for the develo |
Ophthalmology Therapeutics Market Emerging Trends USD 12.34 billion by end 2027 Top Key Players AbbVie Inc., Aerie Pharmaceuticals Inc., Bayer AGThe global ophthalmology therapeutics market is showcasing the evident potential in the mentioned forecasting period. Ophthalmology is the branch of medicine associated with the treatment of eye defects and diseases. Ophthalmology Therapeutics Market to grow by $ 12. 34 billion at |